Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
View Patent ↗Disclosed herein are non-platinum-based (NPB) anti-cancer compounds useful for targeted chemotherapy, e.g., to generate anti-cancer effects for the treatment of cancer and other disorders while having no or minimal toxicity. The compounds N have the general formula I: (I) wherein A represents an aromatic core; at least one of R a and R b is an electron transfer promoter as defined herein, e.g., NH 2 ; and at least one of R c is a leaving group as defined herein, e.g., halogen; and the remainder of the molecule is as defined herein. Pharmaceutical compositions, methods, uses, kits and commercial packages comprising the anti-cancer compounds are also disclosed.
1. A method of treating a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a non-platinum-based (NPB) compound, having the general formula III:
wherein:
X and Y are independently C—R 3 or N;
R 1 is a halogen selected from the group of Cl, Br, I or F;
one of R 2 and R 3 is H, OH, halogen, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl, or heteroaryl, and the other of R 2 and R 3 is H or halogen;
wherein each of the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl and heteroaryl moieties is optionally substituted by one or more functional groups selected from the list consisting of hydroxyl, amino, amido, cyano, nitro, carboxyl, ester, ether, ketone, aldehyde, or a combination thereof;
or a pharmaceutically acceptable salt thereof;
wherein the cancer is selected from a group consisting of: testicular cancer, bladder cancer, cervical cancer, ovarian cancer, breast cancer, prostate cancer, head and neck cancer, lung cancer, pancreatic cancer, stomach cancer, colorectal cancer, liver cancer, esophageal cancer, and brain cancer.
2. The method of claim 1 , wherein at least one of X and Y are C—R 3 and R 3 is H.
3. The method of claim 1 , wherein the compound is selected from the group consisting of:
or
a pharmaceutically acceptable salt thereof.
4. The method of claim 2 , wherein both of X and Y are C—R 3 and R 3 is H.
5. The method of claim 3 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
6. A method of treating myeloma or lymphoma treatable by cisplatin, the method comprising administering a conditioning regimen to a subject in need thereof, prior to a bone marrow transplant or hematopoietic stem cell transplant, wherein the conditioning regimen is comprised of a therapeutically effective amount of the compound having the general formula III:
wherein:
X and Y are independently C—R 3 or N;
R 1 is a halogen selected from the group of Cl, Br, I or F;
one of R 2 and R 3 is H, OH, halogen, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl, or heteroaryl, and the other of R 2 and R 3 is H or halogen;
wherein each of the alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclyl and heteroaryl moieties is optionally substituted by one or more functional groups selected from the list consisting of hydroxyl, amino, amido, cyano, nitro, carboxyl, ester, ether, ketone, aldehyde, or a combination thereof;
or a pharmaceutically acceptable salt thereof;
and one or more pharmaceutically acceptable carriers or diluents.
7. The method of claim 1 , wherein the therapeutically effective amount of the compound is administered with one or more pharmaceutically acceptable carriers or diluents.
8. A method of treating a non-cancer disease or condition selected from the group consisting of: psoriasis, Crohn's disease, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis and lupus erythematosus, comprising administering to a subject in need thereof a therapeutically effective amount of a non-platinum-based (NPB) compound, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 6 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 3 , wherein the compound is administered alone or in conjunction with one or more additional chemotherapeutic agents or cancer therapies, excluding radiation.
11. The method of claim 5 , wherein the compound is administered alone or in conjunction with one or more additional chemotherapeutic agents or cancer therapies, excluding radiation.
12. The method of claim 1 , wherein the cancer is selected from the group consisting of: ovarian cancer, cervical cancer, breast cancer, lung cancer, head and neck cancer, and pancreatic cancer.
13. The method of claim 3 , wherein the cancer is selected from the group consisting of: ovarian cancer, cervical cancer, breast cancer, lung cancer, head and neck cancer, and pancreatic cancer.
14. The method of claim 5 , wherein the cancer is selected from the group consisting of: ovarian cancer, cervical cancer, breast cancer, lung cancer, head and neck cancer, and pancreatic cancer.
15. The method of claim 1 , wherein the compound is administered alone or in conjunction with one or more additional chemotherapeutic agents or cancer therapies, excluding radiation.